Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for ASLAN Pharmaceuticals Ltd. (ASLN : NSDQ)

• Company Description    ASLAN Pharmaceuticals Limited operates as a clinical-stage biotechnology company. It develops drugs, medicines and novel therapeutics for the treatment of patients with oncology, respiratory and inflammatory diseases. The company's product portfolio includes Varlitinib, ASLAN004, ASLAN002 and ASLAN003 both are in clinical stage. ASLAN Pharmaceuticals Limited is based in Singapore. Number of Employees: 27

• Price / Volume Information    Yesterday's Closing Price: $0.46 Daily Weekly Monthly 20 Day Moving Average: 208,174 shares Shares Outstanding: 69.75 (millions) Market Capitalization: $32.29 (millions) Beta: 2.33 52 Week High: $3.87 52 Week Low: $0.42 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -38.67% -32.81% 12 Week -48.56% -44.18% Year To Date -58.66% -50.84%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 83 CLEMENCEAU AVENUE NO 12-03 UE SQUARE - SINGAPORE,U0 239920 SGP ph: 65-6222-4235 fax: 65-6225-2419 investor@aslanpharma.com https://aslanpharma.com

• General Corporate Information    Officers Carl Firth - Chief Executive Officer and Director Andrew Howden - Chairman Kiran Asarpota - Chief Operating Officer and Head of Finance Stephen Doyle - Chief Business Officer Robert E. Hoffman - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04522R101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/05/22 Share - Related Items Shares Outstanding: 69.75 Most Recent Split Date: (:1) Beta: 2.33 Market Capitalization: $32.29 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.20 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.66 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.72 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -46.15% vs. Previous Quarter: -18.75% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -58.72 12/31/21 - -42.37 09/30/21 - -49.32 ROA 03/31/22 - -37.34 12/31/21 - -30.02 09/30/21 - -33.11 Current Ratio 03/31/22 - 9.63 12/31/21 - 14.75 09/30/21 - 16.60 Quick Ratio 03/31/22 - 9.63 12/31/21 - 14.75 09/30/21 - - Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 0.65 12/31/21 - 0.82 09/30/21 - 1.79 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.81 12/31/21 - 0.54 09/30/21 - 0.45 Debt-to-Capital 03/31/22 - 44.69 12/31/21 - 35.00 09/30/21 - 31.17

Powered by Zacks Investment Research ©